List view / Grid view
20 July 2018 | By Darius Widera, Jonathan Sheard, Thamil Selvee Ramasamy
Mesenchymal stem cells (MSCs) are fibroblast-like cells that give rise to mesenchymal derivatives including bone, fat and cartilage cells. In addition to the bone marrow, they can be readily obtained from adult vascularised peripheral tissues including adipose, olfactory, respiratory tissue, and peripheral blood.
20 July 2018 | By Audrey Ncube, James Adjaye (Heinrich-Heine-University), Lisa Nguyen, Lucas-Sebastian Spitzhorn, Martina Bohndorf, Shaifur Rahman, Wasco Wruck (Heinrich-Heine-University)
Kidneys are crucial for filtration of drugs and toxins and their proper function is essential for overall health. Unfortunately, due to disease and improper function, kidney transplantation or dialysis are necessary for millions of patients annually all over the world.1,2
3 July 2018 | By Adam David Thomas
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.
11 June 2018 | By PerkinElmer
For lead optimisation, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological relevance is driving ongoing growth in cell-based assays.
11 June 2018 | By Jeff McMillan (Senior Product Manager Imaging at Molecular Devices)
The global high-content screening (HCS) software and services market accounted for over $500 million in 2017 and is expected to reach approximately $1.4 billion by 2026, increasing at a compound annual growth rate of more than 11%, says Jeff McMillan, Senior Product Manager Imaging, Molecular Devices.
8 June 2018 | By Mark Paris
This webinar focused on a recent study evaluating a cohort of head and neck squamous cell carcinoma (HNSCC) patient tumours treated with anti-PD1 using CANscript™.
8 June 2018 | By Dan Appledorn (Director of US Biology - Essen Bioscience)
The Nobel Prize-winning observations and discoveries of John B. Gurdon and Shinya Yamanaka have ignited an explosion of excitement around the potential use of stem cells in research and treatment of human disease.
8 June 2018 | By Tecan
This webinar, supported by Tecan, focused on the automated assessment of liver and cardiac toxicities in lead optimisation, using biochemical and human iPS cell assays.
7 June 2018 | By Liz Quinn (Associate Director - Stem Cells Marketing at Takara Bio USA)
Human primary hepatocytes (hpheps) are the gold standard for in vitro evaluation of drug metabolism, drug-drug interactions, and metabolic disease research. However, hpheps don’t survive in standard 2D culture for very long – no longer than two or three days.
7 June 2018 | By Dr. Paul Wylie (Head of Applications at TTP Labtech)
For most people, traditional High-Throughput Screening (HTS) represents large automation rigs and large libraries of small molecules screened against drug targets, however, the development of biological therapeutics has been gaining considerable pace for many reasons.
7 June 2018 | By Drug Target Review
The General Data Protection Regulation (GDPR) is a new set of EU rules governing how a company manages, protects and administers personal data. Whether you are a subscriber, author, advertiser or supplier to our journal, we may hold information about you and we need to keep it private and secure.
6 June 2018 | By Laura Goldie - Head of Technical Services - Biogelx Ltd.
Despite their vast therapeutic potential in such areas as cell therapy and tissue engineering, stem cells have yet to live up to their original hype and demonstrate widespread clinical success.
6 June 2018 | By Joseph Zock (Senior Director - Product Management - IntelliCyt -a Sartorius Company)
The demand for new therapeutics is driving efforts to discover novel antibodies and harness their power in both biologics and adoptive cell therapy areas.
6 June 2018 | By Sesha Tekur (Key Accounts Manage/Field Application Specialist at Thermo Fisher Scientific)
For the next generation of cell biologists, 3D cell culture and analysis has opened doors to taking applied research one step further.
5 June 2018 | By Philip Spencer (AstraZeneca)
Advances in genomics and structural biology are providing drug discovery scientists with more biological targets to prosecute, and greater information about each one.
Send this to a friend
Follow: